Advances in the non-surgical treatment of melanoma

Bibliography

• COATES M, TRACEY E: Cancer in New South Wales. Incidence and mortality 1998 and incidence for selected cancer 1999. NSW Central Cancer Registry, Cancer Research and Registers Division, NSW Cancer Council (2001) April:42–43.
   Google Scholar
• ATKINS MB: The treatment of metastatic melanoma with chemotherapy: biologics. Curl: Opin. Oncal. (1997) 9:205–213.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANNELLI JR, YANG JC et al.: Treatment of patients with metastatic melanoma with autologous tumour-infiltrating lymphocytes and interleukin 2.1 Nati Cancer Inst. (1994) 86:1159–1166.
   Google Scholar
• LEE C, THOMPSON JA, ROCHE P et al.: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. I Exp. Med. (2000) 192:1637–1643.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM, MASCARI RA, EDINGTON HD etal.: Analysis of therapeutic and immunologic effects of R(24) anti GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer (2000) 88:2693–2702.
   Google Scholar
• LODE HN, REISFELD RA: Targeted cytokines for cancer immunotherapy. Inanunal. Res. (2000) 21:279–288.
   Google Scholar
• WALLACK MK, SIVANANDHAM M, BALCH CM et al.: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. j. Am. Call. Surg. (1998) 187:69–77.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON PO, WONG GY, ADLURI S et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2. I Clin. Oncal. (1994) 12:1036–1044.
   PubMed Web of Science ®Google Scholar
• SONDAK VK, LIU P-Y, TUTHILL RJ et al.: Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. I. Overall results of a randomized trial of the Southwest Oncology Group. I Chia. Oncal. (2001) Submitted.
   Google Scholar
• KIRKWOOD JM, IBRAHIM JG, SOSMAN JA et al.: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the gm2-klh/qs-21 vaccine in patients with resected stage iib-iii melanoma: results of intergroup trial e1694/s9512/c509801. I Clin. Oncal.(2001) 19:2370–2380.
   PubMed Web of Science ®Google Scholar
• HERSEY E EDWARDS A, COATES A, SHAW H, MCCARTHY W, MILTON G: Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Irranunal. knnunather. (1987) 25:257–265.
   Web of Science ®Google Scholar
• HERSEY P, COATES A,MCCARTHY WH etal.: Adjuvant immunotherapy of patients with high risk melanoma with vaccinia viral lysates of melanoma. Results of a randomized trial. J. Clin. Oncal. (2001) Submitted.
   Google Scholar
• SOSMAN JA, UNGER JM, LIU P-Y et aL:Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. II. Impact of HLA class I antigen expression on outcome. I Clin. Oncal. (2001) Submitted.
   Google Scholar
• KIRKWOOD JM, IBRAHIM JG, SONDAK VK et al.: High- and low -dose Interferon alpha-2b in high-risk melanoma: first analysis of intergroup trial E1690/ 59111/C9190. J Clin. Oncal. (2000) 18:2444–2458.
   PubMed Web of Science ®Google Scholar
• MORTON DL, FOSHAG LJ, HOON DSB et al.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. (1992) 216:463–482.
   PubMed Web of Science ®Google Scholar
• MITCHELL MS: Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semi]. Oncol. (1998) 25:623–635.
   PubMed Web of Science ®Google Scholar
• BERD D, MAGUIRE HC, SCHUCHTER LM et al.: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J. Chit. Oncol. (1997) 15:2359–2370.
   PubMed Web of Science ®Google Scholar
• BYSTRYN JC, ZELENIUCH-JACQUOTTE A, ORATZ R, SHAPIRO RL, HARRIS MN, ROSES DF: Double-blind trial of a polyvalent, shed-antigen, melanoma. Chit. Cancer Res. (2001) 7:1882–1887.
   PubMed Web of Science ®Google Scholar
• EGGERMONT AM: Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eur. J. Cancer (1998) 34:S22–S26.
   PubMed Web of Science ®Google Scholar
• STREET NE, MOSMANN TR: Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB (1991) 5:171–177.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Nati Acad. Li. USA (1993) 90:3539–3543.
   PubMed Web of Science ®Google Scholar
• SOIFFER R,LYNCHT, MIHM M et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Nati Acad. Sci.USA (1998) 95:13141–13146.
   Google Scholar
• MASTRANGELO MJ, MAGUIRE HCJR, EISENLOHR LC et al.: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. (1999) 6:409–422.
   PubMed Web of Science ®Google Scholar
• CHANG AE, LI Q, BISHOP DK, NORMOLLE DP, REDMAN BD, NICKOLOFF BJ: Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. (2000) 11:839–850.
   PubMed Web of Science ®Google Scholar
• ELLEM KA, O'ROURKE MG, JOHNSON GR etal.: A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. (1997) 44:10–20.
   Google Scholar
• PALMER K, MOORE J, EVERARD M et al.: Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. (1999) 10:1261–1268.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, KAMPGEN E, WAGNER E et al.: Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum. Gene Ther. (1999) 10:983–993.
   PubMed Web of Science ®Google Scholar
• FUJII S, HUANG S, FONG TC et al: Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther. (2000) 7:1220–1230.
   PubMed Web of Science ®Google Scholar
• MOLLER P, SUN Y, DORBIC T et al.: Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br. J. Cancer (1998) 77:1907–1916.
   PubMed Web of Science ®Google Scholar
• SUN Y, JURGOVSKY K, MOLLER P et al.: Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther. (1998) 5:481–490.
   PubMed Web of Science ®Google Scholar
• BELLI E ARIENTI F, SULE-SUSO J et al.: Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol. Immunother. (1997) 44:197–203.
   PubMed Web of Science ®Google Scholar
• OSANTO S, SCHIPHORST PP, WEIJL NI etal.: Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. (2000) 11:739–750.
   Google Scholar
• ARIENTI F, BELLI F, NAPOLITANO F et al.: Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. (1999) 10:2907–2916.
   PubMed Web of Science ®Google Scholar
• STOPECK AT, HERSH EM, AKPORIAYE ET et al.: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. j CM]. Oncol. (1997) 15:341–349.
   PubMed Web of Science ®Google Scholar
• RENKVIST N, CASTELLI C, ROBBINS PF, PARMIANI G: A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. (2001) 50:3–15.
   PubMed Web of Science ®Google Scholar
• GUILLOUX Y, LUCAS S, BRICHARD VG etal.: A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. Exp. Med. (1996) 183:1173–1183.
   Google Scholar
• VALMORI D, DUTOIT V, RUBIO-GODOY V et al.: Frequent cytolytic T cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. (2001) 61:509–512.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4:321–327.
   PubMed Web of Science ®Google Scholar
• MARCHAND M, VAN BAREN N, WEYNANTS P etal.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-Al. mt. j Cancer (1999) 80:219–230.
   Google Scholar
• KRUIT WH, VAN BAREN N, HUMBLET Y etal.: Phase I/II study of vaccination with a MAGE-3 protein plus immunological adjuvant SB AS-2 in HLA class I selected patients with MAGE-3 positive tumors. Proceedings ofASCO (2000) 19:479a.
   Google Scholar
• ROSENBERG SA, ZHAI Y, YANG JC etal.: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Nati Cancer Inst. (1998) 90:1894–1900.
   Google Scholar
• RANIERI E, KIERSTEAD LS, ZAROUR H et al.: Dendritic cell/peptide cancer vaccines: clinical responsivene and epitope spreading. Immunol. Invest. (2000) 29:121–125.
   PubMedGoogle Scholar
• JAEGER E, BERNHARD H, ROMERO P et al.: Generation of cytotoxic T cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer (1996) 66:162–169.
   PubMed Web of Science ®Google Scholar
• WEBER JS, HUA FL, SPEARS L, MARTYV, KUNIYOSHI C, CELIS E: A phase I trial of an HLA-Al restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. (1999) 22:431–440.
   PubMed Web of Science ®Google Scholar
• WANG F, BADE E, KUNIYOSHI C et al.:Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. (1999) 5:2756–2765.
   PubMed Web of Science ®Google Scholar
• CEBON JS et al: Phase I studies of immunization with Melan-A and IL-12 in HLA A2+ positive patients with stage III and IV malignant melanoma. Proc. ASCO (1999) 18:434a.
   Google Scholar
• SCHEIBENBOGEN C etal.: Vaccination with tyrosinase peptides and GM-CSF in metastatic melanoma: a phase II trial. Proc. ASCO (1999) 18:436a.
   Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET Met al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328–332.
   Google Scholar
• PANELLI MC, WUNDERLICH J, JEFFRIES J et al.: Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. Immunother. (2000) 23:487–498.
   PubMed Web of Science ®Google Scholar
• THURNER B, HAENDLE I, RODER C et al.: Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. j Exp. Med. (1999) 190:1669–1678.
   PubMed Web of Science ®Google Scholar
• HU X, CHAKRABORTY NG, SPORN JR, KURTZMAN SH, ERGIN MT, MUKHERJI B: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. (1996) 56:2479–2483.
   PubMed Web of Science ®Google Scholar
• CHAKRABORTY N et al: Melanoma cell lysate loaded autologous antigen presenting cell (APC) as a vaccine in melanoma. Proc. Amer. Assoc. Cancer Res. (1997) 38:400.
   Google Scholar
• GAJEWSKI TF, FALLARINO F, VOGELZANG N, POSNER MC, ASHIKARI A,SHERMAN ML: Effective melanoma antigen vaccination without dendritic cells (DC): A phase I study of immunization with Mage3 or Melan-A peptide-pulsed autologous PBMC plus RhIL-12. Proc. ASCO (1999) 18:539a.
   Google Scholar
• THOMAS WD, HERSEY P: TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas Ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. I Immurrol (1998) 161:2195–2200.
   Google Scholar
• ZHANG XD, FRANCO A, MYERS K, GRAY C, NGUYEN T, HERSEY P: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Research (1999) 59:2747–2753.
   PubMed Web of Science ®Google Scholar
• THOMAS WD, ZHANG XD, FRANCO AV, NGUYEN T, HERSEY P: TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. Immurrol (2000) 165:5612–5620.
   Google Scholar
• MACDONALD G, SHI L, VANDE VELDE C, LIEBERMAN J, GREENBERG AH: Mitochondria-dependent and - independent regulation of granzyme B-induced apoptosis. j Exp. Med. (1999) 189:131–143.
   PubMed Web of Science ®Google Scholar
• SUTTON VR, DAVIS JE, CANCILLA M et al.: Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. Exp. Med. (2000) 192:1403–1413.
   PubMed Web of Science ®Google Scholar
• HERSEY P, ZHANG XD: How melanoma cells evade apoptosis. Nature Om. Rev (2001) In Press.
   Google Scholar
• ASHKENAZI A, DIXIT VM: Apoptosis control by death and decoy receptors. Cum: Opirr, Cell Biol. (1999) 11:255–260.
   PubMed Web of Science ®Google Scholar
• COULTAS L, STRASSER A: The molecular control of DNA damage-induced cell death. Apoptosis (2000) 5:491–507.
   PubMed Web of Science ®Google Scholar
• NICHOLSON DW: From bench to clinic with apoptosis-based therapeutic agents. Nature (2000) 407:810–816.
   PubMed Web of Science ®Google Scholar
• ZHANG XD, ZHANG XI, GRAY CI NGUYEN T, HERSEY P: Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Res. (2001) 61:7339–7348.
   PubMed Web of Science ®Google Scholar
• SHEIKH MS, BURNS TF, HUANG Yet al.: p53-dependent and -independent regulation of the death receptor KILLER/ DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. (1998) 58:1593–1598.
   Google Scholar
• NGUYEN T, ZHANG XD,HERSEY P: Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Chu. Cancer Res. (2001) 7:966s–973s.
   Google Scholar
• JANSEN B, SCHLAGBAUER-WADL H, BROWN BD et al: bc1-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. (1998) 4:232–234.
   PubMed Web of Science ®Google Scholar
• TANG L, TRON VA, REED JC et al: Expression of apoptosis regulators in cutaneous malignant melanoma. Chu. Cancer Res. (1998) 4:1865–1871.
   PubMed Web of Science ®Google Scholar
• STRASBERG RIEBER M, ZANGEMEISTER-WITTKE U, RIEBER M: p53-independent induction of apoptosis in human melanoma cells by a bc1-2/bc1-xL bispecific antisense oligonucleotide. Chu. Cancer Res. (2001) 7:1446–1451.
   PubMed Web of Science ®Google Scholar
• MOULDING DA, GILES RV, SPILLER DG, WHITE MR, TIDD DM, EDWARDS SW: Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood (2000) 96: 1756-1763.
   Google Scholar
• BOUCHER M-J, MORISSET J, VACHON PH, REED JC, LAINE J, RIVARD N: MEK/ERK signaling pathway regulates the expression of Bc1-2, Bc1-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells. j Cell. Biol. (2000) 79:355–369.
   Google Scholar
• MANDIC A, VIKTORSSON K, HEIDEN T, HANSSON J, SHOSHAN MC: The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. (2001) 11:11–19.
   PubMed Web of Science ®Google Scholar
• MOLL UM, ZAIKA A: Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett. (2001) 493:65–69.
   PubMed Web of Science ®Google Scholar
• SOENGAS MS, CAPODIECI P, POLSKY D et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 409:207–210.
   PubMed Web of Science ®Google Scholar
• MAYO MW, BALDWIN AS: The transcription factor NF-icB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta (2000) 1470:M55–M62.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, ARA G, HERBST R, PALOMBELLA VJ, ADAMS J: The proteasome inhibitor PS-341 in cancer therapy. Chu. Cancer Res. (1999) 5:2638–2645.
   PubMed Web of Science ®Google Scholar
• SELZER E, PIMENTEL E, WACHECK V et al: Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. j Invest. Dermatol. (2000) 114:935–940.
   PubMed Web of Science ®Google Scholar
• SUN S-Y, YUE P, HONG WK, LOTAN R: Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAM-induced apoptosis by the synthetic retinoid 6-13- (1-Adamanty1)-4-hydroxyphenyll -2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res. (2000) 60:7149–7155.
   PubMed Web of Science ®Google Scholar